{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff278\deff0\stshfdbch0\stshfloch37\stshfhich37\stshfbi37\deflang16393\deflangfe16393\themelang1033\themelangfe0\themelangcs1100{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial;}
{\f2\fbidi \fmodern\fcharset0\fprq1{\*\panose 02070309020205020404}Courier New;}{\f3\fbidi \froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}{\f10\fbidi \fnil\fcharset2\fprq2{\*\panose 05000000000000000000}Wingdings;}
{\f34\fbidi \froman\fcharset0\fprq2{\*\panose 02040503050406030204}Cambria Math;}{\f35\fbidi \fswiss\fcharset128\fprq2{\*\panose 020b0604020202020204}Arial Unicode MS;}{\f37\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}
{\f137\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604030504040204}Tahoma;}{\f157\fbidi \fswiss\fcharset128\fprq2{\*\panose 020b0604020202020204}@Arial Unicode MS;}{\f278\fbidi \froman\fcharset0\fprq2{\*\panose 00000000000000000000}Kartika;}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\fhimajor\f31502\fbidi \froman\fcharset0\fprq2{\*\panose 02040503050406030204}Cambria;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 00000000000000000000}Kartika;}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 00000000000000000000}Kartika;}{\f287\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}
{\f288\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\f290\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\f291\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\f292\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\f293\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\f294\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\f295\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\f297\fbidi \fswiss\fcharset238\fprq2 Arial CE;}
{\f298\fbidi \fswiss\fcharset204\fprq2 Arial Cyr;}{\f300\fbidi \fswiss\fcharset161\fprq2 Arial Greek;}{\f301\fbidi \fswiss\fcharset162\fprq2 Arial Tur;}{\f302\fbidi \fswiss\fcharset177\fprq2 Arial (Hebrew);}
{\f303\fbidi \fswiss\fcharset178\fprq2 Arial (Arabic);}{\f304\fbidi \fswiss\fcharset186\fprq2 Arial Baltic;}{\f305\fbidi \fswiss\fcharset163\fprq2 Arial (Vietnamese);}{\f307\fbidi \fmodern\fcharset238\fprq1 Courier New CE;}
{\f308\fbidi \fmodern\fcharset204\fprq1 Courier New Cyr;}{\f310\fbidi \fmodern\fcharset161\fprq1 Courier New Greek;}{\f311\fbidi \fmodern\fcharset162\fprq1 Courier New Tur;}{\f312\fbidi \fmodern\fcharset177\fprq1 Courier New (Hebrew);}
{\f313\fbidi \fmodern\fcharset178\fprq1 Courier New (Arabic);}{\f314\fbidi \fmodern\fcharset186\fprq1 Courier New Baltic;}{\f315\fbidi \fmodern\fcharset163\fprq1 Courier New (Vietnamese);}{\f627\fbidi \froman\fcharset238\fprq2 Cambria Math CE;}
{\f628\fbidi \froman\fcharset204\fprq2 Cambria Math Cyr;}{\f630\fbidi \froman\fcharset161\fprq2 Cambria Math Greek;}{\f631\fbidi \froman\fcharset162\fprq2 Cambria Math Tur;}{\f634\fbidi \froman\fcharset186\fprq2 Cambria Math Baltic;}
{\f635\fbidi \froman\fcharset163\fprq2 Cambria Math (Vietnamese);}{\f639\fbidi \fswiss\fcharset0\fprq2 Arial Unicode MS Western;}{\f637\fbidi \fswiss\fcharset238\fprq2 Arial Unicode MS CE;}{\f638\fbidi \fswiss\fcharset204\fprq2 Arial Unicode MS Cyr;}
{\f640\fbidi \fswiss\fcharset161\fprq2 Arial Unicode MS Greek;}{\f641\fbidi \fswiss\fcharset162\fprq2 Arial Unicode MS Tur;}{\f642\fbidi \fswiss\fcharset177\fprq2 Arial Unicode MS (Hebrew);}
{\f643\fbidi \fswiss\fcharset178\fprq2 Arial Unicode MS (Arabic);}{\f644\fbidi \fswiss\fcharset186\fprq2 Arial Unicode MS Baltic;}{\f645\fbidi \fswiss\fcharset163\fprq2 Arial Unicode MS (Vietnamese);}
{\f646\fbidi \fswiss\fcharset222\fprq2 Arial Unicode MS (Thai);}{\f657\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\f658\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\f660\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}
{\f661\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}{\f662\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}{\f663\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\f664\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}
{\f665\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}{\f1657\fbidi \fswiss\fcharset238\fprq2 Tahoma CE;}{\f1658\fbidi \fswiss\fcharset204\fprq2 Tahoma Cyr;}{\f1660\fbidi \fswiss\fcharset161\fprq2 Tahoma Greek;}
{\f1661\fbidi \fswiss\fcharset162\fprq2 Tahoma Tur;}{\f1662\fbidi \fswiss\fcharset177\fprq2 Tahoma (Hebrew);}{\f1663\fbidi \fswiss\fcharset178\fprq2 Tahoma (Arabic);}{\f1664\fbidi \fswiss\fcharset186\fprq2 Tahoma Baltic;}
{\f1665\fbidi \fswiss\fcharset163\fprq2 Tahoma (Vietnamese);}{\f1666\fbidi \fswiss\fcharset222\fprq2 Tahoma (Thai);}{\f1859\fbidi \fswiss\fcharset0\fprq2 @Arial Unicode MS Western;}{\f1857\fbidi \fswiss\fcharset238\fprq2 @Arial Unicode MS CE;}
{\f1858\fbidi \fswiss\fcharset204\fprq2 @Arial Unicode MS Cyr;}{\f1860\fbidi \fswiss\fcharset161\fprq2 @Arial Unicode MS Greek;}{\f1861\fbidi \fswiss\fcharset162\fprq2 @Arial Unicode MS Tur;}
{\f1862\fbidi \fswiss\fcharset177\fprq2 @Arial Unicode MS (Hebrew);}{\f1863\fbidi \fswiss\fcharset178\fprq2 @Arial Unicode MS (Arabic);}{\f1864\fbidi \fswiss\fcharset186\fprq2 @Arial Unicode MS Baltic;}
{\f1865\fbidi \fswiss\fcharset163\fprq2 @Arial Unicode MS (Vietnamese);}{\f1866\fbidi \fswiss\fcharset222\fprq2 @Arial Unicode MS (Thai);}{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}
{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}
{\fhimajor\f31528\fbidi \froman\fcharset238\fprq2 Cambria CE;}{\fhimajor\f31529\fbidi \froman\fcharset204\fprq2 Cambria Cyr;}{\fhimajor\f31531\fbidi \froman\fcharset161\fprq2 Cambria Greek;}{\fhimajor\f31532\fbidi \froman\fcharset162\fprq2 Cambria Tur;}
{\fhimajor\f31535\fbidi \froman\fcharset186\fprq2 Cambria Baltic;}{\fhimajor\f31536\fbidi \froman\fcharset163\fprq2 Cambria (Vietnamese);}{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}
{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}
{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}
{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;
\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red96\green94\blue92;\red225\green223\blue221;
\red34\green34\blue34;\red17\green85\blue204;\red102\green0\blue102;}{\*\defchp \f37 }{\*\defpap \ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa200\sl276\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af278\afs22\alang1100 \ltrch\fcs0 \f37\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{
\s1\ql \li0\ri0\sb100\sa100\sbauto1\saauto1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel0\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \ab\af35\afs48\alang1100 \ltrch\fcs0 \b\fs48\lang1033\langfe16393\kerning36\cgrid\langnp1033\langfenp16393 
\sbasedon0 \snext1 \slink15 \sqformat \spriority9 \styrsid3154999 heading 1;}{\*\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv 
\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af37\afs20\alang1025 \ltrch\fcs0 \f37\fs20\lang16393\langfe16393\cgrid\langnp16393\langfenp16393 \snext11 \ssemihidden \sunhideused Normal Table;}{\*\cs15 
\additive \rtlch\fcs1 \af0 \ltrch\fcs0 \b\f0\fs48\kerning36 \sbasedon10 \slink1 \slocked \spriority9 \styrsid3154999 Heading 1 Char;}{\s16\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 
\af35\afs20\alang1100 \ltrch\fcs0 \f37\fs20\lang1033\langfe16393\cgrid\langnp1033\langfenp16393 \sbasedon0 \snext16 \slink17 \ssemihidden \sunhideused \styrsid11360838 footnote text;}{\*\cs17 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \fs20 
\sbasedon10 \slink16 \slocked \ssemihidden \styrsid11360838 Footnote Text Char;}{\*\cs18 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \super \sbasedon10 \ssemihidden \sunhideused \styrsid11360838 footnote reference;}{\*\cs19 \additive \rtlch\fcs1 \af0 
\ltrch\fcs0 \fs16 \sbasedon10 \ssemihidden \sunhideused \styrsid15158618 annotation reference;}{\s20\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af278\afs20\alang1025 \ltrch\fcs0 
\f37\fs20\lang16393\langfe16393\cgrid\langnp16393\langfenp16393 \sbasedon0 \snext20 \slink21 \ssemihidden \sunhideused \styrsid15158618 annotation text;}{\*\cs21 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f37\fs20\lang16393\langfe0\langnp16393\langfenp0 
\sbasedon10 \slink20 \slocked \ssemihidden \styrsid15158618 Comment Text Char;}{\s22\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af35\afs16\alang1100 \ltrch\fcs0 
\f137\fs16\lang1033\langfe16393\cgrid\langnp1033\langfenp16393 \sbasedon0 \snext22 \slink23 \ssemihidden \sunhideused \styrsid15158618 Balloon Text;}{\*\cs23 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f137\fs16 
\sbasedon10 \slink22 \slocked \ssemihidden \styrsid15158618 Balloon Text Char;}{\*\cs24 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \ul\cf2 \sbasedon10 \sunhideused \styrsid4811833 Hyperlink;}{\s25\ql \li720\ri0\sa200\sl276\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin720\itap0\contextualspace \rtlch\fcs1 \af278\afs22\alang1100 \ltrch\fcs0 \f37\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 
\sbasedon0 \snext25 \sqformat \spriority34 \styrsid12855812 List Paragraph;}{\s26\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \ab\af278\afs20\alang1100 \ltrch\fcs0 
\b\f37\fs20\lang16393\langfe16393\cgrid\langnp16393\langfenp16393 \sbasedon20 \snext20 \slink27 \ssemihidden \sunhideused \styrsid3154999 annotation subject;}{\*\cs27 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f37\fs20\lang16393\langfe0\langnp16393\langfenp0 \sbasedon21 \slink26 \slocked \ssemihidden \styrsid3154999 Comment Subject Char;}{\s28\ql \li0\ri0\sa200\sl276\slmult1\widctlpar
\tqc\tx4680\tqr\tx9360\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af35\afs22\alang1100 \ltrch\fcs0 \f37\fs22\lang1033\langfe16393\cgrid\langnp1033\langfenp16393 
\sbasedon0 \snext28 \slink29 \ssemihidden \sunhideused \styrsid4875274 header;}{\*\cs29 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \fs22 \sbasedon10 \slink28 \slocked \ssemihidden \styrsid4875274 Header Char;}{\s30\ql \li0\ri0\sa200\sl276\slmult1\widctlpar
\tqc\tx4680\tqr\tx9360\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af35\afs22\alang1100 \ltrch\fcs0 \f37\fs22\lang1033\langfe16393\cgrid\langnp1033\langfenp16393 \sbasedon0 \snext30 \slink31 \sunhideused \styrsid4875274 
footer;}{\*\cs31 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \fs22 \sbasedon10 \slink30 \slocked \styrsid4875274 Footer Char;}{\*\cs32 \additive \cf17\chshdng0\chcfpat0\chcbpat18 \ssemihidden \sunhideused \styrsid6447696 Unresolved Mention;}}{\*\listtable
{\list\listtemplateid-1503868936\listhybrid{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace360\levelindent0{\leveltext\leveltemplateid-1781389806\'02\'00.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 
\cf1\fbias0 \fi-360\li720\lin720 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698713\'02\'01.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 
\fi-360\li1440\lin1440 }{\listlevel\levelnfc2\levelnfcn2\leveljc2\leveljcn2\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698715\'02\'02.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 
\fi-180\li2160\lin2160 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698703\'02\'03.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 
\fi-360\li2880\lin2880 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698713\'02\'04.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 
\fi-360\li3600\lin3600 }{\listlevel\levelnfc2\levelnfcn2\leveljc2\leveljcn2\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698715\'02\'05.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 
\fi-180\li4320\lin4320 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698703\'02\'06.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 
\fi-360\li5040\lin5040 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698713\'02\'07.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 
\fi-360\li5760\lin5760 }{\listlevel\levelnfc2\levelnfcn2\leveljc2\leveljcn2\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698715\'02\'08.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 
\fi-180\li6480\lin6480 }{\listname ;}\listid114179083}{\list\listtemplateid685265710\listhybrid{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\leveltemplateid-611024922
\'02\'00.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \cf1\fbias0 \fi-360\li720\lin720 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid134807577
\'02\'01.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li1440\lin1440 }{\listlevel\levelnfc2\levelnfcn2\leveljc2\leveljcn2\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid134807579
\'02\'02.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-180\li2160\lin2160 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid134807567
\'02\'03.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li2880\lin2880 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid134807577
\'02\'04.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li3600\lin3600 }{\listlevel\levelnfc2\levelnfcn2\leveljc2\leveljcn2\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid134807579
\'02\'05.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-180\li4320\lin4320 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid134807567
\'02\'06.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li5040\lin5040 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid134807577
\'02\'07.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li5760\lin5760 }{\listlevel\levelnfc2\levelnfcn2\leveljc2\leveljcn2\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid134807579
\'02\'08.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-180\li6480\lin6480 }{\listname ;}\listid1189877493}{\list\listtemplateid1776069290\listhybrid{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat5\levelspace0
\levelindent0{\leveltext\leveltemplateid134807577\'02\'00.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fbias0 \fi-360\li720\lin720 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0
{\leveltext\leveltemplateid134807577\'02\'01.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li1440\lin1440 }{\listlevel\levelnfc2\levelnfcn2\leveljc2\leveljcn2\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\leveltemplateid134807579\'02\'02.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-180\li2160\lin2160 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\leveltemplateid134807567\'02\'03.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li2880\lin2880 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\leveltemplateid134807577\'02\'04.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li3600\lin3600 }{\listlevel\levelnfc2\levelnfcn2\leveljc2\leveljcn2\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\leveltemplateid134807579\'02\'05.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-180\li4320\lin4320 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\leveltemplateid134807567\'02\'06.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li5040\lin5040 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\leveltemplateid134807577\'02\'07.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li5760\lin5760 }{\listlevel\levelnfc2\levelnfcn2\leveljc2\leveljcn2\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\leveltemplateid134807579\'02\'08.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-180\li6480\lin6480 }{\listname ;}\listid1844541637}{\list\listtemplateid1102080726{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1
\levelspace0\levelindent0{\leveltext\'01\u-3913 ?;}{\levelnumbers;}\f3\fs20\fbias0 \fi-360\li720\jclisttab\tx720\lin720 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\'01o;}{\levelnumbers;}\f2\fs20\fbias0 \fi-360\li1440\jclisttab\tx1440\lin1440 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\'01\u-3929 ?;}{\levelnumbers;}
\f10\fs20\fbias0 \fi-360\li2160\jclisttab\tx2160\lin2160 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\'01\u-3929 ?;}{\levelnumbers;}\f10\fs20\fbias0 \fi-360\li2880
\jclisttab\tx2880\lin2880 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\'01\u-3929 ?;}{\levelnumbers;}\f10\fs20\fbias0 \fi-360\li3600\jclisttab\tx3600\lin3600 }
{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\'01\u-3929 ?;}{\levelnumbers;}\f10\fs20\fbias0 \fi-360\li4320\jclisttab\tx4320\lin4320 }{\listlevel\levelnfc23\levelnfcn23
\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\'01\u-3929 ?;}{\levelnumbers;}\f10\fs20\fbias0 \fi-360\li5040\jclisttab\tx5040\lin5040 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0
\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\'01\u-3929 ?;}{\levelnumbers;}\f10\fs20\fbias0 \fi-360\li5760\jclisttab\tx5760\lin5760 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative
\levelspace0\levelindent0{\leveltext\'01\u-3929 ?;}{\levelnumbers;}\f10\fs20\fbias0 \fi-360\li6480\jclisttab\tx6480\lin6480 }{\listname ;}\listid1967730878}}{\*\listoverridetable{\listoverride\listid1189877493\listoverridecount0\ls1}
{\listoverride\listid1844541637\listoverridecount0\ls2}{\listoverride\listid114179083\listoverridecount0\ls3}{\listoverride\listid1967730878\listoverridecount0\ls4}}{\*\pgptbl {\pgp\ipgp0\itap0\li0\ri0\sb0\sa0}{\pgp\ipgp0\itap0\li0\ri0\sb0\sa0}{\pgp\ipgp0
\itap0\li0\ri0\sb0\sa0}{\pgp\ipgp0\itap0\li0\ri0\sb0\sa0}{\pgp\ipgp0\itap0\li0\ri0\sb0\sa0}}{\*\rsidtbl \rsid4283\rsid80148\rsid137490\rsid139189\rsid155534\rsid162597\rsid213296\rsid1116279\rsid1186783\rsid1210110\rsid1212169\rsid1376385\rsid1401365
\rsid1457235\rsid1585105\rsid1639844\rsid1658285\rsid2175553\rsid2650541\rsid3154999\rsid3176344\rsid3414217\rsid3874944\rsid3935693\rsid4465874\rsid4811833\rsid4856539\rsid4875274\rsid4928182\rsid5066659\rsid5075010\rsid5653106\rsid5927117\rsid6039430
\rsid6052213\rsid6172346\rsid6447696\rsid6567658\rsid6648540\rsid6768748\rsid6769858\rsid7351265\rsid7352658\rsid8398789\rsid8418598\rsid8462109\rsid8726617\rsid8748824\rsid8799835\rsid8923256\rsid9114192\rsid9703230\rsid9855092\rsid10040112\rsid10303415
\rsid10435991\rsid10557204\rsid10769158\rsid10970164\rsid11217350\rsid11292261\rsid11341066\rsid11360838\rsid11430663\rsid11553481\rsid11806721\rsid11929718\rsid12091271\rsid12147659\rsid12154455\rsid12783167\rsid12794109\rsid12855812\rsid13002387
\rsid13006350\rsid13052058\rsid13369851\rsid13525771\rsid13647066\rsid13778448\rsid13784713\rsid13855155\rsid14556230\rsid14621910\rsid14752918\rsid15089580\rsid15158618\rsid15227867\rsid15675228\rsid15824775\rsid16001246\rsid16546201\rsid16591566
\rsid16674806}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\author M Ramanathan}{\operator Reviewer}{\creatim\yr2019\mo11\dy29\hr18\min34}
{\revtim\yr2019\mo11\dy29\hr18\min34}{\version2}{\edmins0}{\nofpages7}{\nofwords2577}{\nofchars14694}{\*\company sctimst}{\nofcharsws17237}{\vern57433}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}
\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont1\relyonvml0\donotembedlingdata0\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1\noxlattoyen
\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1440\dgvorigin1440\dghshow1\dgvshow1
\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\snaptogridincell\allowfieldendsel\wrppunct
\asianbrkrule\rsidroot6648540\newtblstyruls\nogrowautofit\utinl \fet0{\*\wgrffmtfilter 2450}\ilfomacatclnup0
{\*\docvar {EN.InstantFormat}{<ENInstantFormat><Enabled>1</Enabled><ScanUnformatted>1</ScanUnformatted><ScanChanges>1</ScanChanges></ENInstantFormat>}}
{\*\docvar {EN.Libraries}{<ENLibraries><Libraries><item>Gene_therapy_IJME.enl</item></Libraries></ENLibraries>}}{\*\ftnsep \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid11360838 
\rtlch\fcs1 \af278\afs22\alang1100 \ltrch\fcs0 \f37\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af278 \ltrch\fcs0 \insrsid155534 \chftnsep 
\par }}{\*\ftnsepc \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid11360838 \rtlch\fcs1 \af278\afs22\alang1100 \ltrch\fcs0 \f37\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {
\rtlch\fcs1 \af278 \ltrch\fcs0 \insrsid155534 \chftnsepc 
\par }}{\*\aftnsep \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid11360838 \rtlch\fcs1 \af278\afs22\alang1100 \ltrch\fcs0 \f37\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {
\rtlch\fcs1 \af278 \ltrch\fcs0 \insrsid155534 \chftnsep 
\par }}{\*\aftnsepc \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid11360838 \rtlch\fcs1 \af278\afs22\alang1100 \ltrch\fcs0 \f37\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {
\rtlch\fcs1 \af278 \ltrch\fcs0 \insrsid155534 \chftnsepc 
\par }}\ltrpar \sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\footerr \ltrpar \pard\plain \ltrpar\s30\qr \li0\ri0\sa200\sl276\slmult1\widctlpar\tqc\tx4680\tqr\tx9360\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 
\rtlch\fcs1 \af35\afs22\alang1100 \ltrch\fcs0 \f37\fs22\lang1033\langfe16393\cgrid\langnp1033\langfenp16393 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid1116279\charrsid4875274  PAGE   \\* MERGEFORMAT }}{\fldrslt {\rtlch\fcs1 \af1 
\ltrch\fcs0 \f1\lang1024\langfe1024\noproof\insrsid12794109 1}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid1116279\charrsid4875274 
\par }\pard \ltrpar\s30\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\tqc\tx4680\tqr\tx9360\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 {\rtlch\fcs1 \af35 \ltrch\fcs0 \insrsid1116279 
\par }}{\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}
{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8
\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}\pard\plain \ltrpar\ql \li0\ri0\sa200\sl276\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid13369851 \rtlch\fcs1 \af278\afs22\alang1100 \ltrch\fcs0 \f37\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid3414217\charrsid13369851 Comments on the d}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid14556230\charrsid13369851 raft }{\rtlch\fcs1 \af0\afs24 
\ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11430663\charrsid13369851 ICMR }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid14556230\charrsid13369851 
guidelines for gene therapy product development and clinical trials }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid3414217\charrsid13369851 2019 }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid14556230\charrsid13369851 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13647066\charrsid13369851 Anoopkumar Thekkuveettil, Srikant }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid5653106\charrsid13369851 A }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid13647066\charrsid13369851 and Mala Ramanathan}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid8726617\charrsid13369851 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11292261\charrsid13369851 Anoopkumar Thekkuveettil:}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid11292261\charrsid13369851 
 Scientist G, Division of Molecular Medicine, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram 695012, Kerala. Email: }{\field\flddirty{\*\fldinst {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid155534 HYPERLINK "../../../Downloads/anoop@sctimst.ac.in"}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid155534\charrsid13369851 {\*\datafield 
00d0c9ea79f9bace118c8200aa004ba90b0200000001000000e0c9ea79f9bace118c8200aa004ba90b660000002e002e002f002e002e002f002e002e002f0044006f0077006e006c006f006100640073002f0061006e006f006f007000400073006300740069006d00730074002e00610063002e0069006e000000795881f4
3b1d7f48af2c825dc485276300000000a5ab0003}}}{\fldrslt {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \cs24\f0\fs24\ul\cf2\insrsid11292261\charrsid13369851 anoop@sctimst.ac.in}}}\sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 
\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid11292261\charrsid13369851  Ph. 0471 2520256
\par }\pard\plain \ltrpar\s16\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid13369851 \rtlch\fcs1 \af35\afs20\alang1100 \ltrch\fcs0 \f37\fs20\lang1033\langfe16393\cgrid\langnp1033\langfenp16393 {\rtlch\fcs1 
\ab\af0\afs24 \ltrch\fcs0 \b\f0\fs24\lang1033\langfe0\langfenp0\insrsid13525771\charrsid13369851 Srikant A:}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe0\langfenp0\insrsid13525771\charrsid13369851  }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\lang1033\langfe0\langfenp0\insrsid11292261\charrsid13369851 Assistant Professor, Achutha Menon Centre for Health Science Studies, SCTIMST, Medical College PO, Thiruvananthapuram 695011, KERALA. Email: }{\field\flddirty{\*\fldinst {\rtlch\fcs1 
\af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe0\langfenp0\insrsid11292261\charrsid13369851  HYPERLINK "mailto:asrikant@sctimst.ac.in" }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe0\langfenp0\insrsid12794109\charrsid13369851 {\*\datafield 
00d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90b540000006d00610069006c0074006f003a0061007300720069006b0061006e007400400073006300740069006d00730074002e00610063002e0069006e000000795881f43b1d7f48af2c825dc485276300000000a5ab
0003}}}{\fldrslt {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \cs24\f0\fs24\ul\cf2\lang1033\langfe0\langfenp0\insrsid11292261\charrsid13369851 asrikant@sctimst.ac.in}}}\sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0\afs24 
\ltrch\fcs0 \f0\fs24\lang1033\langfe0\langfenp0\insrsid11292261\charrsid13369851  }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe0\langfenp0\insrsid13369851\charrsid13369851 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe0\langfenp0\insrsid11292261\charrsid13369851 Ph. 0471 2524233
\par 
\par }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \b\f0\fs24\lang1033\langfe0\langfenp0\insrsid13525771\charrsid13369851 Mala Ramanathan:}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe0\langfenp0\insrsid13525771\charrsid13369851  }{\rtlch\fcs1 
\af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe0\langfenp0\insrsid11292261\charrsid13369851 Professor, Achutha Menon Centre for Health Science Studies, SCTIMST, Medical College PO, Thiruvananthapuram 695011, KERALA. Email: }{\field\flddirty{\*\fldinst {
\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe0\langfenp0\insrsid11292261\charrsid13369851  HYPERLINK "mailto:mala@sctimst.ac.in" }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe0\langfenp0\insrsid12794109\charrsid13369851 
{\*\datafield 
00d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90b4c0000006d00610069006c0074006f003a006d0061006c006100400073006300740069006d00730074002e00610063002e0069006e000000795881f43b1d7f48af2c825dc485276300000000a5ab0003}}}{\fldrslt 
{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \cs24\f0\fs24\ul\cf2\lang1033\langfe0\langfenp0\insrsid11292261\charrsid13369851 mala@sctimst.ac.in}}}\sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\lang1033\langfe0\langfenp0\insrsid11292261\charrsid13369851  }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe0\langfenp0\insrsid13369851\charrsid13369851 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe0\langfenp0\insrsid11292261\charrsid13369851 Ph. 0471 2524234
\par }\pard\plain \ltrpar\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid13369851 \rtlch\fcs1 \af278\afs22\alang1100 \ltrch\fcs0 \f37\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {
\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11292261\charrsid13369851 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 Competing interests:
\par }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
Dr.Anoop Kumar Thekkuveettil, Dr.A Srikant and Dr.Mala Ramanathan do not have any competing interests, financial or otherwise with any firm developing gene therapy products. 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 Funding support:
\par }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 This commentary has not received any funding support from any agency}{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid1401365\charrsid13369851  or individual}{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
. This has been undertaken as part of an exercise to provide comments on the draft guidelines }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11292261\charrsid13369851 made pub
licly available by the Indian Council for Medical Research}{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid1401365\charrsid13369851 , New Delhi}{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11292261\charrsid13369851 .
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11292261\charrsid13369851 S}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid11292261\charrsid13369851 
ubmissions of very similar work, with references to the previous submission if applicable:
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid11292261\charrsid13369851 Two of the authors, of this commentary, Dr.A Srikant and Dr.Mala Ramanathan submitted online 
comments to the concerned office at the ICMR in response to the public call for comments on the guidelines.
\par }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11292261\charrsid13369851 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid12091271\charrsid13369851 \page }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851  }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 Comments on the draft ICMR guidelines for gene therapy product development and clinical trials 2019 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851 Twenty years after Jesse Gelsinger\rquote s death i
n a gene therapy clinical trial, such experiments have become better regulated. When he died on Sept 17 1999, Gelsinger was participating in the first gene therapy clinical trial on a rare genetic disorder \endash 
 Ornithine Transcabalmylase (OTC) deficiency. Such patients usually get only symptomatic treatment and have no curative options. These conditions have early onset \endash 
 usually at childhood and this means a prolonged battle against the adverse consequences for both the patient and the families. Pharmaceutical companies often ignore these ra}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13002387\charrsid13369851 r}
{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851 e genetic disorders such as Gelsinger\rquote 
s because of the complexities involved and the limited number of patients with such diseases.  The only option left for them becomes gene therapy. Probably that is why m
ore than the required number of patients were willing to enroll in the OTC trial and Gelsinger himself waited for a year to reach the age of 18 to enroll in it. We now know that the adnovirus used in the OTC trial causes high immune reactions, but the new
 
generation options like Adeno-associated virus (AAV) do not induce high immune reactions, are non-pathogenic and harmless. These AAV have been found effective in non-dividing cells, allowing one to target genetic diseases affecting the nervous system.   P
a
tients suffereing from beta-thalassemia, when treated with a single dose of Lenti-Globin viral vector containing the corrected gene, could eliminate or reduce the blood transfusions needed (1). In 2018, the gene therapy update indicated that there were 65
7 trials in Phase I, 509 in Phase I/II, 455 in Phase II, 89 in Phase III and 38 in Phase IV trials (2). Almost 20 years after Gelsinger\rquote s death, gene therapy stood persuasive \endash 
 as more and rarer diseases and disorders could benefit from gene therapy and saf
er vectors for delivery are available.  This is not to say that concerns regarding safety do not exist. The potential harms stem from the fact that the very technology that seems predictable in pre-clinical models may have unforeseen adverse consequences 
in human beings. 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid16591566 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851 
Self inactiviting vectors without their own promoters are considered safe, but selecting an appropriate one is a challenge. Retrovirus based vectors may cross the Weisemann barrier (3) and pass the information from somatic to germ cells. 
This is considered problematic because not only is the effect experinced by the target individual, but this change may be transmitted to the next genera}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13002387\charrsid13369851 t}{\rtlch\fcs1 
\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851 ion. 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf19\chshdng0\chcfpat0\chcbpat8\insrsid16591566 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf19\chshdng0\chcfpat0\chcbpat8\insrsid13778448\charrsid13369851 Clustered Regularly Interspaced Short Palindromic Repeats}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851  (CRISPR)-Cas9-}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851  a gene editing technolo
gy which has the potential to do that has already cerated a furore about editing the germline for preventing HIV-AIDS. While CRISPR is not a preferred method for gene editing, it is only a matter of time before it enters the fray through better designed e
xperimental protocols. At least four CRISPR trials each currently involving one or two patients with long term follow-up are already underway in the US (4) and it will be not long before the same needs are raised by researchers in India. 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid16591566 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851 The US Food and D
rug Adminstration (US FDA) has attempted to develop gudielines to regulate gene therapy and it has released drafts for three disease specific gene therapy guidelines, }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 a) human gene therapy for haemophilia, b) human gene therapy for retinal disorders, and c
) human gene therapy for rare diseases. Besides, FDA has drafted guidelines on the manufacturing of gene therapies. This includes}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid16591566 :}{\rtlch\fcs1 \af0\afs24 
\ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851  
\par a) chemistry, manufacturing and control information for human gene therapy investigational new drug application (}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851 HYPERLINK "
https://www.fda.gov/media/113760/download"}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid12794109\charrsid13369851 {\*\datafield 
00d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90b6c000000680074007400700073003a002f002f007700770077002e006600640061002e0067006f0076002f006d0065006400690061002f003100310033003700360030002f0064006f0077006e006c006f0061006400
0000795881f43b1d7f48af2c825dc485276300000000a5ab0003}}}{\fldrslt {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\ul\cf20\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 https://www.fda.gov/media/113760/download}}}\sectd \ltrsect
\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
) b) testing of retroviral-vector based gene therapy products for replication competent retrovirus during product manufacture and patient followup (}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851 
HYPERLINK "https://www.fda.gov/media/113790/download"}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid12794109\charrsid13369851 {\*\datafield 
00d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90b6c000000680074007400700073003a002f002f007700770077002e006600640061002e0067006f0076002f006d0065006400690061002f003100310033003700390030002f0064006f0077006e006c006f0061006400
0000795881f43b1d7f48af2c825dc485276300000000a5ab0003}}}{\fldrslt {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\ul\cf20\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 https://www.fda.gov/media/113790/download}}}\sectd \ltrsect
\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 ) and c) long term followup after administration of human gene therapy products (}
{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851 HYPERLINK "https://www.fda.gov/media/113768/download"}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid12794109\charrsid13369851 {\*\datafield 
00d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90b6c000000680074007400700073003a002f002f007700770077002e006600640061002e0067006f0076002f006d0065006400690061002f003100310033003700360038002f0064006f0077006e006c006f0061006400
0000795881f43b1d7f48af2c825dc485276300000000a5ab0003}}}{\fldrslt {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\ul\cf20\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 https://www.fda.gov/media/113768/download}}}\sectd \ltrsect
\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 ).\~
These guidelines for manufacturing insist on a mandatory phase IV long term monitoring for gene therapy involving genome editing. This was envisaged to check on the long term potential of retroviruses to activate itself in the later stages of its life cyc
le. 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe2057\langfenp2057\insrsid16591566 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 The Government of India through the ageis of the Indian Council for Medical Research (ICMR) has released the draft {\*\bkmkstart OLE_LINK1}
{\*\bkmkstart OLE_LINK2}National Guidelines for Gene Therapy Project Development and Clincial Trials{\*\bkmkend OLE_LINK1}{\*\bkmkend OLE_LINK2}, merging the reulations for project development and testing it into one regulation. }{\rtlch\fcs1 \af0\afs24 
\ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
The ICMR has requested responses from the stakeholders to the document. Such discussions would generate an inclusive engagement and thus enable finalisation of the guidelines with a more rigourou
s scrutiny. This note is a comment on these guidelines which we hope will contribute to the process of its improvement.
\par }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid16591566 
\par }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 Indian draft national Guidelines for Gene Therapy Product Development and Clinical Trials\~
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 The draft Indian Guidelines are similar to the National Institutes of Health guidelines in this context, known as the 84 FR 17858 (5). }{
\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 The initiative to draft such a guideline is timely and appropriate.\~
The present guideline covers both the scientific requirments and the ethical challenges. Although it is limited in terms of the regulatory requirements}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid3874944\charrsid13369851 , e}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
thical regulations for clinical trials are well defined in India under various guidelines from ICMR and statuary laws.\~}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\delrsid6039430\charrsid13369851  }{
\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 Regulations for product development and cli
nical trials provide a framework and accountability for a scientifically proven method/technique with societal checks and balances for sound human research and trials. Often, public policy and regulation on the use of technology, particularly its use in i
m
proving health, has emerged out of controversy rather than preparedness. An example of this is the Pre-Conception and Pre-Natal Diagnostic Techniques (PCPNDT) Act, 1994 which came into existence after activists called attention to declines in sex ratio at
 birth in some states in India, where sex determination and sex selective abortions were being practiced.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid16591566 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
It is encouraging to note that the guidelines on Gene Therapy represent a welcome departure in this context. The ICMR guidelines that set the framewor
k for Gene therapy product development and clinical trials are a timely intervention by the scientific departments of the Government of India. This has the potential to guide researchers working in this area within the country. However, the guidelines are
 not specific to meet the requirements of targeted gene therapy guidelines that the US FDA has released for manufacturing of gene therapies. By merging the requirements for manufacturing with those of clincial trials, this draft \lquote }{\rtlch\fcs1 
\af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 National Guidelines for Gene Therapy Project Development and Clincial Trials\rquote }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851  lacks the distinct requirements for each of these processes.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 

\par }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid16591566 
\par }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 What does the guideline lack clarity on?\~
\par }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid16591566 
\par }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 Developing appropriate biomarkers for evaluating outcomes: }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 The present guidelines on }{\rtlch\fcs1 \ai\af0\afs24 \ltrch\fcs0 \i\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 Gene therapy Pr
oduct (GTP) Development and clinical trials}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
 require the use of only pre-clinically validated gene therapy products before carrying out first in human clinical trials in a limited sample of individuals. 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid16591566 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 The guidelines lack clarity on developing biomarkers
 as different readouts during the gene therapy trials. It also does not state the frequency of followup and special consent requirement for their continued participation and regular tests for various markers, including gene expression markers. This follow
up should last for 15 years.\~(Comment on: Section 11.5.2.7, Page 60 of the draft guidelines) }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid16591566 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 Rather than leaving it vague as \lquote 
traditional clinical readouts may not be available and hence, sponsors are strongly encouraged to establish novel readouts for therapeutic efficacy}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid3874944\charrsid13369851 \rquote }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
, the guidelines could be more specific about the require
ment. It is better to specify that sponsors should consider gene therapy biomarkers for trials in the preclinical stage and follow promising biomarkers for first in human trials on a regular interval until the study period ends. This needs to include the 
v
iral replication markers, because that is, one the eminent threat of the technology. For CRISPR-Cas9, there must be checkpoints for proper integration of gene on the site of interest and to assay inadvertent DNA breaks by Cas-9, another unanticipated cons
equence of the technique allowing induction of new recombinations which also need assessment. The frequency of checks for tumor formation or any unrelated disease development is essential. (Comment on: Section 11.5.2.7, Page 60 of the draft guidelines) }{
\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \b\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid16591566 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
Consent processes for long term engagement and patient safety: It is also essential to have a more elaborate consenting process for gene therapy. The guideline needs to emphasise a detailed account on the risks and benefits of gene therapy to the particip
ants; the need for long term follow up; consequences of discontinuation from study follow-up or continuous treatment. The participants should be made aware }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid3874944\charrsid13369851 through}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851  the consenting process that }{\rtlch\fcs1 
\ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851 discontinuation of the gene therapy does not absolve them from lo
ng term follow-up. This is because the follow-up is not merely for clinical data purposes, but also from a perspective of individual patient safety needs. The guideline needs to stress on this point.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid16591566 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 Counseling services: Predicting the long term outcomes 
of gene therapy is yet to occur. Considering this, there will be high psychological stress among the participants compared to any other trials.  This calls for including a genetic and psychological counselor in the study team.\~
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid16591566 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 Optimizing sample size requ
irements: Since effects of gene therapy could be far-reaching, investigators must exercise extreme caution. Safety must be ensured by including a small number of the patient}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid3874944\charrsid13369851 s}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
 before enhancing the number of enrolled patients. One limitation of gene therapy trials, as seen in Gelsinger\rquote 
s case, is unpredictability in linking the preclinical data to predict the consequences of a clinical trial. On the other hand, successful preclinical testing is a primer for human trials and hence, efforts of developing biomar
kers in preclinical testing often help, to a larger extent, in identifying the possible risk during human trials. 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid16591566 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 Using expert reviewers: }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
Gene therapy targets will be very specific rare diseases, often with highly personalized modifications based on the 
mutations in the patient, it would be ideal to have experts in those disease areas to review the study. Besides, clinicial investigators need to undergo specific training in research ethics before undertaking such studies. 
\par Including references to existing ethics guidelines:}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid3874944\charrsid13369851 T}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 he guideline has been drafted as an independent document, not often referring to the existing human research guidelines in the country}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid3874944\charrsid13369851 . It therefore}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851  generates confusion }{\rtlch\fcs1 \af0\afs24 
\ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid3874944\charrsid13369851 with respect to}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
 compensation to study patients in case of any SAE d
uring a gene therapy trial. We find no mention of the link to the existing rules for compensation via the New Drugs and Clinical Trials Rules 2019 notified in March 2019. Rather than assuming upon the potential link through recourse to the existing legal 
frameworks in the guidance, it would be prudent to state the need for compensation explicitly in the guideline.\~
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid16591566 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 Preparing for germline gene therapy: The guideline mentions that germline and }{\rtlch\fcs1 \ai\af0\afs24 \ltrch\fcs0 
\i\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 in utero}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
 gene therapy is prohibited in India. However, it will be helpful for the scientific community to know if this will be reviewed in the future in accordance with the recently published global moratorium on germline gene editing (6).\~}{\rtlch\fcs1 
\ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851 This is important to note as the groundwork for germline and in utero gene therap
y has to be done earlier if we are to be technologically prepared for the future by linking it to case by case review through an apex body such as the GTAEC.
\par }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid16591566 
\par }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851 Separating guidelines product development from clinical trials for Gene Therapy: }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
The guideline is a shared document for both clinical conduct of gene therapy as well as gene therapy product development. Though the guideline has adapted the product development part, to a large extent from the FDA documents, it needs more clarity. For e
x
ample, one of the major concerns in retroviral therapy is to ensure that the vectors lack replication competency (replication competent retrovirus -RCR). The guideline, however, mentions this critical requirement in one sentence without much elaboration. 
It would be ideal to the split this guideline into two: one for gene therapy product development and one for the clinical trials. This would allow a more comprehensive listing of the requirement and checkpoints.\~
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid16591566 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 These caveats apart, the guidance on Gene T
herapy Product Development and Clinical Trials represents a welcome effort for medical professionals, scientists and biotechnology industries providing the scientific and ethical bounds for their research. Researchers can keep pushing }{\rtlch\fcs1 
\af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid4465874\charrsid13369851 these boundries }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 throu
gh technological innovation in gene therapy for the benefit of human kind, but at least now they know where the lines are drawn.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid16591566 
\par 
\par 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 References:
\par {\listtext\pard\plain\ltrpar \rtlch\fcs1 \af0\alang1100 \ltrch\fcs0 \cf1\lang1033\langfe1033\langnp1033\langfenp1033\insrsid13778448\charrsid13369851 \hich\af0\dbch\af0\loch\f0 1.\tab}}\pard \ltrpar\ql \fi-360\li720\ri0\sa200\sl276\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\ls3\adjustright\rin0\lin720\itap0\pararsid13369851 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851 
Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil JA, Hongeng S, et al. Gene Therapy in Patients with Transfusion-Dependent beta-Thalassemia. N Engl J Med.  Apr 19;378(16):1479-93.
\par {\listtext\pard\plain\ltrpar \rtlch\fcs1 \af0\alang1100 \ltrch\fcs0 \cf1\lang1033\langfe1033\langnp1033\langfenp1033\insrsid13778448\charrsid13369851 \hich\af0\dbch\af0\loch\f0 2.\tab}Philippidis A. }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af0\afs24 
\ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851  HYPERLINK "https://www.genengnews.com/a-lists/25-up-and-coming-gene-therapies/" }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid12794109\charrsid13369851 {\*\datafield 
00d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90ba0000000680074007400700073003a002f002f007700770077002e00670065006e0065006e0067006e006500770073002e0063006f006d002f0061002d006c0069007300740073002f00320035002d00750070002d00
61006e0064002d0063006f006d0069006e0067002d00670065006e0065002d007400680065007200610070006900650073002f000000795881f43b1d7f48af2c825dc485276300000000a5ab0003}}}{\fldrslt {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\cs24\f0\fs24\ul\cf2\insrsid13778448\charrsid13369851 https://www.genengnews.com/a-lists/25-up-and-coming-gene-therapies/}}}\sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid13778448\charrsid13369851 
\par {\listtext\pard\plain\ltrpar \rtlch\fcs1 \af0\alang1100 \ltrch\fcs0 \cf1\lang1033\langfe1033\langnp1033\langfenp1033\insrsid13778448\charrsid13369851 \hich\af0\dbch\af0\loch\f0 3.\tab}Surani MA. }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\insrsid13778448\charrsid13369851 Breaking the germ line-soma barrier. }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\chshdng0\chcfpat0\chcbpat8\insrsid13778448\charrsid13369851 
 HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/26860363" \\o "Nature reviews. Molecular cell biology." }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\chshdng0\chcfpat0\chcbpat8\insrsid12794109\charrsid13369851 {\*\datafield 
10d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90b72000000680074007400700073003a002f002f007700770077002e006e006300620069002e006e006c006d002e006e00690068002e0067006f0076002f007000750062006d00650064002f0032003600380036003000
3300360033000000795881f43b1d7f48af2c825dc485276300000000a5ab0003}}}{\fldrslt {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \cs24\f0\fs24\ul\cf21\chshdng0\chcfpat0\chcbpat8\insrsid13778448\charrsid13369851 Nat Rev Mol Cell Biol.}}}\sectd \ltrsect
\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\chshdng0\chcfpat0\chcbpat8\insrsid13778448\charrsid13369851 \~2016 Mar;17(3):136.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid13778448\charrsid13369851 
\par {\listtext\pard\plain\ltrpar \rtlch\fcs1 \af0\alang1100 \ltrch\fcs0 \cf1\lang1033\langfe1033\langnp1033\langfenp1033\insrsid13778448\charrsid13369851 \hich\af0\dbch\af0\loch\f0 4.\tab}
Thulin, L, 2019. Four US CRISPR Trials Editing Human DNA to Research New Treatments, Smithsonina.Com.
\par {\listtext\pard\plain\ltrpar \rtlch\fcs1 \af0\alang1100 \ltrch\fcs0 \cf1\lang1033\langfe1033\langnp1033\langfenp1033\insrsid13778448\charrsid13369851 \hich\af0\dbch\af0\loch\f0 5.\tab}
National Institutes of Health, 2019. NIH Guidelines for Research Involoving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines), Department of Health and Human Services, National Institutes of Health, Bethesda, MD, URL: }
{\field\flddirty{\*\fldinst {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851  HYPERLINK "https://osp.od.nih.gov/wp-content/uploads/NIH_Guidelines.pdf" }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid12794109\charrsid13369851 {\*\datafield 
00d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90b92000000680074007400700073003a002f002f006f00730070002e006f0064002e006e00690068002e0067006f0076002f00770070002d0063006f006e00740065006e0074002f00750070006c006f00610064007300
2f004e00490048005f00470075006900640065006c0069006e00650073002e007000640066000000795881f43b1d7f48af2c825dc485276300000000a5ab0003}}}{\fldrslt {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \cs24\f0\fs24\ul\cf2\insrsid13778448\charrsid13369851 
https://osp.od.nih.gov/wp-content/uploads/NIH_Guidelines.pdf}}}\sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851  accessed on August 31 2019.  }{\rtlch\fcs1 
\af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 
\par {\listtext\pard\plain\ltrpar \rtlch\fcs1 \af0\alang1100 \ltrch\fcs0 \cf1\lang1033\langfe2057\langnp1033\langfenp2057\insrsid13778448\charrsid13369851 \hich\af0\dbch\af0\loch\f0 6.\tab}Lan
der ES, Baylis F, Zhang F, Charpentier E, Berg P, Bourgain C, et al. Adopt a moratorium on heritable genome editing. Nature. Mar;567(7747):165-8.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851 
\par }\pard \ltrpar\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid13369851 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid13778448\charrsid13369851 

\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid11292261\charrsid13369851 Abstract
\par The draft National Guidelines for Gene Therapy Project Development and Clincial Trials combine guidance }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid4465874\charrsid13369851 on }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid11292261\charrsid13369851 product development and testing. }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid4465874\charrsid13369851 T}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid11292261\charrsid13369851 herefore }{
\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid4465874\charrsid13369851 it }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid11292261\charrsid13369851 lacks the specificity }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid4465874\charrsid13369851 r}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid11292261\charrsid13369851 equired for each of these processes. Developing distinct guidelines }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11292261\charrsid13369851 allow }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid4465874\charrsid13369851 for}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11292261\charrsid13369851  more comprehensive listing of the requirements and checkpoints.\~
There is lack of clarity on developing biomarkers as different readouts during the gene therapy trials. As long term outcomes of gene therapy are yet to occur, participants }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid4465874\charrsid13369851 should }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11292261\charrsid13369851 receive genetic and psychological counselling a
nd follow up }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid4465874\charrsid13369851 for mitigating }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11292261\charrsid13369851 potential distress. To avoid exposing more than necessary participants to the experiments, investigators must }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid4465874\charrsid13369851 optimise }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11292261\charrsid13369851 the sample size. }{\rtlch\fcs1 \af0\afs24 
\ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid4465874\charrsid13369851 Eventhough germline }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11292261\charrsid13369851 and }{\rtlch\fcs1 
\ai\af0\afs24 \ltrch\fcs0 \i\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11292261\charrsid13369851 in utero}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11292261\charrsid13369851 
 gene therapy is prohibited in}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid4465874\charrsid13369851  }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid11292261\charrsid13369851 it will be helpful to know if this will be reviewed in the future}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\cf1\lang1033\langfe2057\langfenp2057\insrsid4465874\charrsid13369851  }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid11292261\charrsid13369851 if }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid4465874\charrsid13369851 
researchers are }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid11292261\charrsid13369851 to be technologically prepared for the future. Regardless of these caveats, }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid4465874\charrsid13369851 
the guidelines provide }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid11292261\charrsid13369851 researchers }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid4465874\charrsid13369851 with a }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid11292261\charrsid13369851 potential regulatory frame for their work.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid13778448\charrsid13369851  ADDIN EN.REFLIST }}{\fldrslt }}\sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid13778448\charrsid13369851 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid1116279\charrsid13369851 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid1116279\charrsid13369851  ADDIN EN.REFLIST }}{\fldrslt }}\sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid15158618\charrsid13369851 
\par }{\*\themedata 504b030414000600080000002100e9de0fbfff0000001c020000130000005b436f6e74656e745f54797065735d2e786d6cac91cb4ec3301045f748fc83e52d4a
9cb2400825e982c78ec7a27cc0c8992416c9d8b2a755fbf74cd25442a820166c2cd933f79e3be372bd1f07b5c3989ca74aaff2422b24eb1b475da5df374fd9ad
5689811a183c61a50f98f4babebc2837878049899a52a57be670674cb23d8e90721f90a4d2fa3802cb35762680fd800ecd7551dc18eb899138e3c943d7e503b6
b01d583deee5f99824e290b4ba3f364eac4a430883b3c092d4eca8f946c916422ecab927f52ea42b89a1cd59c254f919b0e85e6535d135a8de20f20b8c12c3b0
0c895fcf6720192de6bf3b9e89ecdbd6596cbcdd8eb28e7c365ecc4ec1ff1460f53fe813d3cc7f5b7f020000ffff0300504b030414000600080000002100a5d6
a7e7c0000000360100000b0000005f72656c732f2e72656c73848fcf6ac3300c87ef85bd83d17d51d2c31825762fa590432fa37d00e1287f68221bdb1bebdb4f
c7060abb0884a4eff7a93dfeae8bf9e194e720169aaa06c3e2433fcb68e1763dbf7f82c985a4a725085b787086a37bdbb55fbc50d1a33ccd311ba548b6309512
0f88d94fbc52ae4264d1c910d24a45db3462247fa791715fd71f989e19e0364cd3f51652d73760ae8fa8c9ffb3c330cc9e4fc17faf2ce545046e37944c69e462
a1a82fe353bd90a865aad41ed0b5b8f9d6fd010000ffff0300504b0304140006000800000021006b799616830000008a0000001c0000007468656d652f746865
6d652f7468656d654d616e616765722e786d6c0ccc4d0ac3201040e17da17790d93763bb284562b2cbaebbf600439c1a41c7a0d29fdbd7e5e38337cedf14d59b
4b0d592c9c070d8a65cd2e88b7f07c2ca71ba8da481cc52c6ce1c715e6e97818c9b48d13df49c873517d23d59085adb5dd20d6b52bd521ef2cdd5eb9246a3d8b
4757e8d3f729e245eb2b260a0238fd010000ffff0300504b03041400060008000000210096b5ade296060000501b0000160000007468656d652f7468656d652f
7468656d65312e786d6cec594f6fdb3614bf0fd87720746f6327761a07758ad8b19b2d4d1bc46e871e698996d850a240d2497d1bdae38001c3ba618715d86d87
615b8116d8a5fb34d93a6c1dd0afb0475292c5585e9236d88aad3e2412f9e3fbff1e1fa9abd7eec70c1d1221294fda5efd72cd4324f1794093b0eddd1ef62fad
79482a9c0498f184b4bd2991deb58df7dfbb8ad755446282607d22d771db8b944ad79796a40fc3585ee62949606ecc458c15bc8a702910f808e8c66c69b9565b
5d8a314d3c94e018c8de1a8fa94fd05093f43672e23d06af89927ac06762a049136785c10607758d9053d965021d62d6f6804fc08f86e4bef210c352c144dbab
999fb7b4717509af678b985ab0b6b4ae6f7ed9ba6c4170b06c788a705430adf71bad2b5b057d03606a1ed7ebf5babd7a41cf00b0ef83a6569632cd467faddec9
699640f6719e76b7d6ac355c7c89feca9cccad4ea7d36c65b258a206641f1b73f8b5da6a6373d9c11b90c537e7f08dce66b7bbeae00dc8e257e7f0fd2badd586
8b37a088d1e4600ead1ddaef67d40bc898b3ed4af81ac0d76a197c86826828a24bb318f3442d8ab518dfe3a20f000d6458d104a9694ac6d88728eee2782428d6
0cf03ac1a5193be4cbb921cd0b495fd054b5bd0f530c1931a3f7eaf9f7af9e3f45c70f9e1d3ff8e9f8e1c3e3073f5a42ceaa6d9c84e5552fbffdeccfc71fa33f
9e7ef3f2d117d57859c6fffac327bffcfc793510d26726ce8b2f9ffcf6ecc98baf3efdfdbb4715f04d814765f890c644a29be408edf3181433567125272371be
15c308d3f28acd249438c19a4b05fd9e8a1cf4cd296699771c393ac4b5e01d01e5a30a787d72cf1178108989a2159c77a2d801ee72ce3a5c545a6147f32a9979
3849c26ae66252c6ed637c58c5bb8b13c7bfbd490a75330f4b47f16e441c31f7184e140e494214d273fc80900aedee52ead87597fa824b3e56e82e451d4c2b4d
32a423279a668bb6690c7e9956e90cfe766cb37b077538abd27a8b1cba48c80acc2a841f12e698f13a9e281c57911ce298950d7e03aba84ac8c154f8655c4f2a
f074481847bd804859b5e696007d4b4edfc150b12addbecba6b18b148a1e54d1bc81392f23b7f84137c2715a851dd0242a633f900710a218ed715505dfe56e86
e877f0034e16bafb0e258ebb4faf06b769e888340b103d3311da9750aa9d0a1cd3e4efca31a3508f6d0c5c5c398602f8e2ebc71591f5b616e24dd893aa3261fb
44f95d843b5974bb5c04f4edafb95b7892ec1108f3f98de75dc97d5772bdff7cc95d94cf672db4b3da0a6557f70db629362d72bcb0431e53c6066acac80d699a
6409fb44d08741bdce9c0e4971624a2378cceaba830b05366b90e0ea23aaa241845368b0eb9e2612ca8c742851ca251ceccc70256d8d87265dd96361531f186c
3d9058edf2c00eafe8e1fc5c509031bb4d680e9f39a3154de0accc56ae644441edd76156d7429d995bdd88664a9dc3ad50197c38af1a0c16d684060441db0256
5e85f3b9660d0713cc48a0ed6ef7dedc2dc60b17e92219e180643ed27acffba86e9c94c78ab90980d8a9f0913ee49d62b512b79626fb06dccee2a432bbc60276
b9f7dec44b7904cfbca4f3f6443ab2a49c9c2c41476dafd55c6e7ac8c769db1bc399161ee314bc2e75cf8759081743be1236ec4f4d6693e5336fb672c5dc24a8
c33585b5fb9cc24e1d4885545b58463634cc5416022cd19cacfccb4d30eb45296023fd35a458598360f8d7a4003bbaae25e331f155d9d9a5116d3bfb9a95523e
51440ca2e0088dd844ec6370bf0e55d027a012ae264c45d02f708fa6ad6da6dce29c255df9f6cae0ec38666984b372ab5334cf640b37795cc860de4ae2816e95
b21be5ceaf8a49f90b52a51cc6ff3355f47e0237052b81f6800fd7b802239daf6d8f0b1571a8426944fdbe80c6c1d40e8816b88b8569082ab84c36ff0539d4ff
6dce591a26ade1c0a7f669880485fd484582903d284b26fa4e2156cff62e4b9265844c4495c495a9157b440e091bea1ab8aaf7760f4510eaa69a6465c0e04ec6
9ffb9e65d028d44d4e39df9c1a52ecbd3607fee9cec7263328e5d661d3d0e4f62f44acd855ed7ab33cdf7bcb8ae889599bd5c8b3029895b6825696f6af29c239
b75a5bb1e6345e6ee6c28117e73586c1a2214ae1be07e93fb0ff51e133fb65426fa843be0fb515c187064d0cc206a2fa926d3c902e907670048d931db4c1a449
59d366ad93b65abe595f70a75bf03d616c2dd959fc7d4e6317cd99cbcec9c58b34766661c7d6766ca1a9c1b327531486c6f941c638c67cd22a7f75e2a37be0e8
2db8df9f30254d30c1372581a1f51c983c80e4b71ccdd28dbf000000ffff0300504b0304140006000800000021000dd1909fb60000001b010000270000007468
656d652f7468656d652f5f72656c732f7468656d654d616e616765722e786d6c2e72656c73848f4d0ac2301484f78277086f6fd3ba109126dd88d0add40384e4
350d363f2451eced0dae2c082e8761be9969bb979dc9136332de3168aa1a083ae995719ac16db8ec8e4052164e89d93b64b060828e6f37ed1567914b284d2624
52282e3198720e274a939cd08a54f980ae38a38f56e422a3a641c8bbd048f7757da0f19b017cc524bd62107bd5001996509affb3fd381a89672f1f165dfe5141
73d9850528a2c6cce0239baa4c04ca5bbabac4df000000ffff0300504b01022d0014000600080000002100e9de0fbfff0000001c020000130000000000000000
0000000000000000005b436f6e74656e745f54797065735d2e786d6c504b01022d0014000600080000002100a5d6a7e7c0000000360100000b00000000000000
000000000000300100005f72656c732f2e72656c73504b01022d00140006000800000021006b799616830000008a0000001c0000000000000000000000000019
0200007468656d652f7468656d652f7468656d654d616e616765722e786d6c504b01022d001400060008000000210096b5ade296060000501b00001600000000
000000000000000000d60200007468656d652f7468656d652f7468656d65312e786d6c504b01022d00140006000800000021000dd1909fb60000001b01000027
00000000000000000000000000a00900007468656d652f7468656d652f5f72656c732f7468656d654d616e616765722e786d6c2e72656c73504b050600000000050005005d0100009b0a00000000}
{\*\colorschememapping 3c3f786d6c2076657273696f6e3d22312e302220656e636f64696e673d225554462d3822207374616e64616c6f6e653d22796573223f3e0d0a3c613a636c724d
617020786d6c6e733a613d22687474703a2f2f736368656d61732e6f70656e786d6c666f726d6174732e6f72672f64726177696e676d6c2f323030362f6d6169
6e22206267313d226c743122207478313d22646b3122206267323d226c743222207478323d22646b322220616363656e74313d22616363656e74312220616363
656e74323d22616363656e74322220616363656e74333d22616363656e74332220616363656e74343d22616363656e74342220616363656e74353d22616363656e74352220616363656e74363d22616363656e74362220686c696e6b3d22686c696e6b2220666f6c486c696e6b3d22666f6c486c696e6b222f3e}
{\*\latentstyles\lsdstimax371\lsdlockeddef0\lsdsemihiddendef0\lsdunhideuseddef0\lsdqformatdef0\lsdprioritydef99{\lsdlockedexcept \lsdqformat1 \lsdpriority0 \lsdlocked0 Normal;\lsdqformat1 \lsdpriority9 \lsdlocked0 heading 1;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 2;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 3;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 4;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 5;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 6;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 7;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 8;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 9;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 1;
\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 2;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 3;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 4;
\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 5;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 6;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 7;
\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 8;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 9;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority35 \lsdlocked0 caption;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Number;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List 4;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List 5;\lsdqformat1 \lsdpriority10 \lsdlocked0 Title;
\lsdsemihidden1 \lsdunhideused1 \lsdpriority1 \lsdlocked0 Default Paragraph Font;\lsdqformat1 \lsdpriority11 \lsdlocked0 Subtitle;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Salutation;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Date;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Body Text First Indent;\lsdqformat1 \lsdpriority22 \lsdlocked0 Strong;\lsdqformat1 \lsdpriority20 \lsdlocked0 Emphasis;\lsdpriority59 \lsdlocked0 Table Grid;\lsdsemihidden1 \lsdlocked0 Placeholder Text;
\lsdqformat1 \lsdpriority1 \lsdlocked0 No Spacing;\lsdpriority60 \lsdlocked0 Light Shading;\lsdpriority61 \lsdlocked0 Light List;\lsdpriority62 \lsdlocked0 Light Grid;\lsdpriority63 \lsdlocked0 Medium Shading 1;\lsdpriority64 \lsdlocked0 Medium Shading 2;
\lsdpriority65 \lsdlocked0 Medium List 1;\lsdpriority66 \lsdlocked0 Medium List 2;\lsdpriority67 \lsdlocked0 Medium Grid 1;\lsdpriority68 \lsdlocked0 Medium Grid 2;\lsdpriority69 \lsdlocked0 Medium Grid 3;\lsdpriority70 \lsdlocked0 Dark List;
\lsdpriority71 \lsdlocked0 Colorful Shading;\lsdpriority72 \lsdlocked0 Colorful List;\lsdpriority73 \lsdlocked0 Colorful Grid;\lsdpriority60 \lsdlocked0 Light Shading Accent 1;\lsdpriority61 \lsdlocked0 Light List Accent 1;
\lsdpriority62 \lsdlocked0 Light Grid Accent 1;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 1;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 1;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 1;\lsdsemihidden1 \lsdlocked0 Revision;
\lsdqformat1 \lsdpriority34 \lsdlocked0 List Paragraph;\lsdqformat1 \lsdpriority29 \lsdlocked0 Quote;\lsdqformat1 \lsdpriority30 \lsdlocked0 Intense Quote;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 1;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 1;
\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 1;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 1;\lsdpriority70 \lsdlocked0 Dark List Accent 1;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 1;\lsdpriority72 \lsdlocked0 Colorful List Accent 1;
\lsdpriority73 \lsdlocked0 Colorful Grid Accent 1;\lsdpriority60 \lsdlocked0 Light Shading Accent 2;\lsdpriority61 \lsdlocked0 Light List Accent 2;\lsdpriority62 \lsdlocked0 Light Grid Accent 2;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 2;
\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 2;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 2;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 2;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 2;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 2;
\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 2;\lsdpriority70 \lsdlocked0 Dark List Accent 2;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 2;\lsdpriority72 \lsdlocked0 Colorful List Accent 2;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 2;
\lsdpriority60 \lsdlocked0 Light Shading Accent 3;\lsdpriority61 \lsdlocked0 Light List Accent 3;\lsdpriority62 \lsdlocked0 Light Grid Accent 3;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 3;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 3;
\lsdpriority65 \lsdlocked0 Medium List 1 Accent 3;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 3;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 3;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 3;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 3;
\lsdpriority70 \lsdlocked0 Dark List Accent 3;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 3;\lsdpriority72 \lsdlocked0 Colorful List Accent 3;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 3;\lsdpriority60 \lsdlocked0 Light Shading Accent 4;
\lsdpriority61 \lsdlocked0 Light List Accent 4;\lsdpriority62 \lsdlocked0 Light Grid Accent 4;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 4;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 4;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 4;
\lsdpriority66 \lsdlocked0 Medium List 2 Accent 4;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 4;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 4;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 4;\lsdpriority70 \lsdlocked0 Dark List Accent 4;
\lsdpriority71 \lsdlocked0 Colorful Shading Accent 4;\lsdpriority72 \lsdlocked0 Colorful List Accent 4;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 4;\lsdpriority60 \lsdlocked0 Light Shading Accent 5;\lsdpriority61 \lsdlocked0 Light List Accent 5;
\lsdpriority62 \lsdlocked0 Light Grid Accent 5;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 5;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 5;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 5;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 5;
\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 5;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 5;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 5;\lsdpriority70 \lsdlocked0 Dark List Accent 5;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 5;
\lsdpriority72 \lsdlocked0 Colorful List Accent 5;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 5;\lsdpriority60 \lsdlocked0 Light Shading Accent 6;\lsdpriority61 \lsdlocked0 Light List Accent 6;\lsdpriority62 \lsdlocked0 Light Grid Accent 6;
\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 6;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 6;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 6;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 6;
\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 6;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 6;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 6;\lsdpriority70 \lsdlocked0 Dark List Accent 6;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 6;
\lsdpriority72 \lsdlocked0 Colorful List Accent 6;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 6;\lsdqformat1 \lsdpriority19 \lsdlocked0 Subtle Emphasis;\lsdqformat1 \lsdpriority21 \lsdlocked0 Intense Emphasis;
\lsdqformat1 \lsdpriority31 \lsdlocked0 Subtle Reference;\lsdqformat1 \lsdpriority32 \lsdlocked0 Intense Reference;\lsdqformat1 \lsdpriority33 \lsdlocked0 Book Title;\lsdsemihidden1 \lsdunhideused1 \lsdpriority37 \lsdlocked0 Bibliography;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority39 \lsdlocked0 TOC Heading;\lsdpriority41 \lsdlocked0 Plain Table 1;\lsdpriority42 \lsdlocked0 Plain Table 2;\lsdpriority43 \lsdlocked0 Plain Table 3;\lsdpriority44 \lsdlocked0 Plain Table 4;
\lsdpriority45 \lsdlocked0 Plain Table 5;\lsdpriority40 \lsdlocked0 Grid Table Light;\lsdpriority46 \lsdlocked0 Grid Table 1 Light;\lsdpriority47 \lsdlocked0 Grid Table 2;\lsdpriority48 \lsdlocked0 Grid Table 3;\lsdpriority49 \lsdlocked0 Grid Table 4;
\lsdpriority50 \lsdlocked0 Grid Table 5 Dark;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 1;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 1;
\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 1;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 1;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 1;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 1;
\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 1;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 2;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 2;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 2;
\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 2;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 2;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 2;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 2;
\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 3;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 3;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 3;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 3;
\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 3;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 3;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 3;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 4;
\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 4;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 4;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 4;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 4;
\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 4;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 4;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 5;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 5;
\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 5;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 5;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 5;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 5;
\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 5;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 6;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 6;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 6;
\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 6;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 6;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 6;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 6;
\lsdpriority46 \lsdlocked0 List Table 1 Light;\lsdpriority47 \lsdlocked0 List Table 2;\lsdpriority48 \lsdlocked0 List Table 3;\lsdpriority49 \lsdlocked0 List Table 4;\lsdpriority50 \lsdlocked0 List Table 5 Dark;
\lsdpriority51 \lsdlocked0 List Table 6 Colorful;\lsdpriority52 \lsdlocked0 List Table 7 Colorful;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 1;\lsdpriority47 \lsdlocked0 List Table 2 Accent 1;\lsdpriority48 \lsdlocked0 List Table 3 Accent 1;
\lsdpriority49 \lsdlocked0 List Table 4 Accent 1;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 1;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 1;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 1;
\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 2;\lsdpriority47 \lsdlocked0 List Table 2 Accent 2;\lsdpriority48 \lsdlocked0 List Table 3 Accent 2;\lsdpriority49 \lsdlocked0 List Table 4 Accent 2;
\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 2;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 2;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 2;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 3;
\lsdpriority47 \lsdlocked0 List Table 2 Accent 3;\lsdpriority48 \lsdlocked0 List Table 3 Accent 3;\lsdpriority49 \lsdlocked0 List Table 4 Accent 3;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 3;
\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 3;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 3;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 4;\lsdpriority47 \lsdlocked0 List Table 2 Accent 4;
\lsdpriority48 \lsdlocked0 List Table 3 Accent 4;\lsdpriority49 \lsdlocked0 List Table 4 Accent 4;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 4;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 4;
\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 4;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 5;\lsdpriority47 \lsdlocked0 List Table 2 Accent 5;\lsdpriority48 \lsdlocked0 List Table 3 Accent 5;
\lsdpriority49 \lsdlocked0 List Table 4 Accent 5;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 5;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 5;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 5;
\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 6;\lsdpriority47 \lsdlocked0 List Table 2 Accent 6;\lsdpriority48 \lsdlocked0 List Table 3 Accent 6;\lsdpriority49 \lsdlocked0 List Table 4 Accent 6;
\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 6;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 6;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 6;}}{\*\datastore 010500000200000018000000
4d73786d6c322e534158584d4c5265616465722e362e30000000000000000000000e0000
d0cf11e0a1b11ae1000000000000000000000000000000003e000300feff0900060000000000000000000000010000000100000000000000001000000200000001000000feffffff0000000000000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
fffffffffffffffffdffffff04000000feffffff05000000fefffffffeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffff52006f006f007400200045006e00740072007900000000000000000000000000000000000000000000000000000000000000000000000000000000000000000016000500ffffffffffffffff010000000c6ad98892f1d411a65f0040963251e5000000000000000000000000c0f1
ab96b5a6d5010300000080020000000000004d0073006f004400610074006100530074006f0072006500000000000000000000000000000000000000000000000000000000000000000000000000000000001a000101ffffffffffffffff020000000000000000000000000000000000000000000000c0f1ab96b5a6d501
c0f1ab96b5a6d50100000000000000000000000030003500c400db00c8004800c800c600d10045004b004100cf005600d7005000c200d300d3004200ca0051003d003d000000000000000000000000000000000032000101ffffffffffffffff030000000000000000000000000000000000000000000000c0f1ab96b5a6
d501c0f1ab96b5a6d5010000000000000000000000004900740065006d0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000a000201ffffffff04000000ffffffff000000000000000000000000000000000000000000000000
00000000000000000000000000000000d800000000000000010000000200000003000000feffffff0500000006000000070000000800000009000000feffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff3c623a536f75726365732053656c65637465645374796c653d225c4150412e58534c22205374796c654e616d653d224150412220786d6c6e733a623d22687474703a2f2f736368656d61732e6f70656e786d6c666f726d6174732e6f7267
2f6f6666696365446f63756d656e742f323030362f6269626c696f6772617068792220786d6c6e733d22687474703a2f2f736368656d61732e6f70656e786d6c666f726d6174732e6f72672f6f6666696365446f63756d656e742f323030362f6269626c696f677261706879223e3c2f623a536f75726365733e00000000
0000000000000000000000000000000000000000000000000000000000000000000000003c3f786d6c2076657273696f6e3d22312e302220656e636f64696e673d225554462d3822207374616e64616c6f6e653d226e6f223f3e0d0a3c64733a6461746173746f72654974656d2064733a6974656d49443d227b41303342
463936392d323637412d343243342d383042442d3544434638423343433141397d2220786d6c6e733a64733d22687474703a2f2f736368656d61732e6f70656e786d6c666f726d6174732e6f72672f6f6666696365446f63756d656e742f323030362f637573746f6d586d6c223e3c64733a736368656d61526566733e3c
64733a736368656d615265662064733a7572693d22687474703a2f2f736368656d61732e6f70656e500072006f007000650072007400690065007300000000000000000000000000000000000000000000000000000000000000000000000000000000000000000016000200ffffffffffffffffffffffff000000000000
0000000000000000000000000000000000000000000000000000000000000400000055010000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000ffffffffffffffffffffffff00000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000ffffffffffffffffffffffff0000
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000ffffffffffffffffffffffff
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000786d6c666f726d6174732e6f72672f6f6666696365446f63756d656e742f323030362f6269626c696f677261706879222f3e3c2f64733a736368656d61526566733e3c2f64733a6461746173746f
72654974656d3e0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000105000000000000}}